Navigation Links
Discovery of reprogramming signature may help further stem cell-based regenerative medicine research
Date:9/19/2012

LA JOLLA, CA---- Salk scientists have identified a unique molecular signature in induced pluripotent stem cells (iPSCs), "reprogrammed" cells that show great promise in regenerative medicine thanks to their ability to generate a range of body tissues.

In this week's Proceedings of the National Academy of Sciences, the Salk scientists and their collaborators at University of California, San Diego, report that there is a consistent, signature difference between embryonic and induced pluripotent stem cells. The findings could help overcome hurdles to using the induced stem cells in regenerative medicine.

"We believe that iPSCs hold a great potential for the treatment of human patients," says Juan Carlos Izpisua Belmonte, a professor in Salk's Gene Expression Laboratory and the senior author on the paper. "Yet we must thoroughly understand the molecular mechanisms governing their safety profile in order to be confident of their function in the human body. With the discovery of these small, yet apparent, epigenetic differences, we believe that we are now one step closer to that goal."

Embryonic stem cells (ESCs) are known for their "pluripotency," the ability to differentiate into nearly any cell in the body. Because of this ability, it has long been thought that ESCs would be ideal to customize for therapeutic uses. However, when ESCs mature into specific cell types, and are then transplanted into a patient, they may elicit immune responses, potentially causing the patient to reject the cells.

In 2006, scientists discovered how to revert mature cells, which had already differentiated into particular cell types, such as skin cells or hair cells, back into a pluripotent state. These "induced pluripotent stem cells" (iPSCs), which could be developed from the patient's own cells, would theoretically carry no risk of immune rejection.

However, scientists found that iPSCs had molecular differences from embryonic stem cells. Specifically, there were epigenetic changes, chemical modifications in DNA that might alter genetic activity. At certain points in the iPSC's genome, scientists could see the presence of different patterns of methyl groups when compared to the genomes of ESCs. It seemed these changes occurred randomly.

Izpisua Belmonte and his colleagues wanted to understand more about these differences. Were they truly random, or was there a discernable pattern?

Unlike previous studies, which had primarily analyzed iPSCs derived from only one mature type of cells (mainly connective tissue cells called fibroblasts), the Salk and UCSD researchers examined iPSCs derived from six different mature cell types to see if there were any commonalities. They discovered that while there were hundreds of unpredictable changes, there were some that remained consistent across the cell types: the same nine genes were associated with these common changes in all iPSCs.

"We knew there were differences between iPSCs and ESCs," says Sergio Ruiz, first author of the paper, "We now have an identifying mark for what they are."

The therapeutic significance of these nine genes awaits further research. The importance of the current study is that it gives stem cells researchers a new and more precise understanding of iPSCs.


'/>"/>

Contact: Andy Hoang
ahoang@salk.edu
619-861-5811
Salk Institute
Source:Eurekalert  

Related biology news :

1. King Richard III search in new phase after discovery has potential to rewrite history
2. New discovery related to gum disease
3. Cant smell anything? This discovery may give you hope
4. Chemicals today, drugs tomorrow: U-Ms new Center for Drug Discovery
5. Molecular movies may accelerate anti-cancer drug discovery
6. Gene discovery could improve treatment for acute myeloid leukemia
7. New discovery of how carbon is stored in the Southern Ocean
8. Gene discovery set to help with mysterious paralysis of childhood
9. 3-D tumor models improve drug discovery success rate
10. OHSU discovery may lead to new treatment for ALS
11. Groundbreaking discovery of mechanism that controls obesity, atherosclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Discovery of reprogramming signature may help further stem cell-based regenerative medicine research
(Date:11/28/2016)... LONDON , Nov. 28, 2016 ... at a rate of 16.79%" The biometric system ... to grow further in the near future. The biometric ... 32.73 billion in 2022, at a CAGR of 16.79% ... biometrics system, integration of biometric technology in smartphones, rising ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , ... December 08, 2016 , ... ... the business of innovation is taking over sports. On Thursday, December 15th a ... how technology is disrupting the playing field at a Smart Talk session. Smart ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and type 2 ... license for a novel adeno-associated virus (AAV) vector ... Kay , M.D., Ph.D., at Stanford University. The ... of its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, ... The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard 204-pin ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
Breaking Biology Technology: